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Abstract: Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is widely used for analgesia and anesthesia 
in obstetric and pediatric practice. Recent reports indicate that ketamine causes neuronal cell death in developing rodents 
and nonhuman primates. The present study assessed the potential dose- and time-dependent neurotoxic effects and associ-
ated changes in gene expression after ketamine administration to postnatal day 7 (PND-7) rat pups.  
Pups were exposed to ketamine subcutaneously at doses of 5, 10, or 20 mg/kg, in one, three or six injections respectively. 
Control animals received the same volume of saline at the same time points. The animals were sacrificed 6 h after the  
last ketamine or saline administration and brain tissues were collected for RNA isolation and histochemical examination. 
Six injections of 20 mg/kg ketamine significantly increased neuronal cell death in frontal cortex, while lower doses and 
fewer injections did not show significant effects. The ketamine induced cell death seemed to be apoptotic in nature. In situ 
hybridization demonstrated that NMDA receptor NR1 subunit expression was dramatically increased in the frontal cortex 
of ketamine treated rats. Microarray analysis revealed altered expression of apoptotic relevant genes and increased NMDA 
receptor gene expression in brains from ketamine treated animals. Quantitative RT-PCR confirmed the microarray results. 
These data suggest that repeated exposures to high doses of ketamine can cause compensatory up-regulation of NMDA 
receptors and subsequently trigger apoptosis in developing neurons. 
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INTRODUCTION 
  Ketamine is an N-methyl-D-aspartate (NMDA) receptor 
ion channel blocker that is being widely used in obstetric and 
pediatric anesthesia. It is short acting and provides rapid dis-
sociative anesthesia followed by rapid recovery. It received 
FDA approval in 1970 for use as an anesthetic in adults.   
Initially, interest in the effect of NMDA-receptor antagonists 
on the developing brain was focused on preventing hypoxic/ 
ischemic brain damage [1]. Subsequent studies, however, 
suggested that, in the developing brain, NMDA-receptor 
antagonists may also have direct neurotoxic effects. After   
the first report on neurotoxic effects of NMDA-receptor   
antagonists in rats during the early stage of central nervous 
system (CNS) development  [2], the possible toxic effects of 
ketamine on the immature brain have been more extensively 
explored. It appears that during rapid synaptogenesis, or   
the brain growth spurt period, neurons are very sensitive   
to perturbations in their synaptic environment. In rodents,   
the brain growth spurt period occurs during the first 3 weeks 
after birth and is characterized by a rapid increase in brain 
weight and proliferation of astroglial and oligodendroglial 
cells [3], etc. To address concerns that findings from rodents 
may not be relevant to humans (the development of the CNS 
in rodents is quite different from that of humans), nonhuman 
primates have been used to assess the neurotoxicity of 
 
*Address correspondence to this author at the Division of Neurotoxicology, 
National Center for Toxicological Research/FDA 3900 NCTR Road   
Jefferson, AR 72079-9502, USA; Tel: 870-543-7259; Fax: 870-543-7576; 
E-mail: Cheng.Wang@fda.hhs.gov 
NMDA receptor antagonists on pre- and postnatal neurons 
[4, 5]. Results from nonhuman primates that are consistent 
with rodent findings accentuate concerns about the potential 
side-effects of NMDA receptor antagonists in humans.   
Although much evidence now indicates a direct relationship 
between blockade of NMDA receptors and neurodegenera-
tion, the underlying mechanism(s) remain(s) unclear. It   
has been postulated that the elevated neuronal cell death   
induced by ketamine may involve a compensatory upregula-
tion of NMDA receptor subunits and subsequent over-
stimulation of the glutamatergic system by endogenous   
glutamate [4, 6, 7]. 
  DNA microarray technology has been widely used to 
obtain gene expression profiles and recently has been incor-
porated into toxicological research. It allows for the simulta-
neous assessment of alterations in the expression of tens of 
thousands of genes in a single experiment. Together with 
other bioinformatics tools, this technology has been widely 
used to investigate the mechanisms of toxicant action, to 
search for novel biomarkers of toxicity and to build molecu-
lar signatures or models for predictive toxicology [8]. Thus, 
DNA microarray technology should provide a relatively 
complete picture of how the NMDA antagonist, ketamine, 
affects gene expression in developing brains and give clues 
about the possible pathways through which ketamine induces 
neurodegeneration. In the present study, we assessed keta-
mine-induced neuropathological and neurobiological out-
comes in infant rats treated with ketamine and used DNA 
microarray technology to explore associated changes in gene 
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MATERIALS AND METHODS 
Ketamine Treatment 
  Seven-day-old (PND-7) Sprague Dawley (male and fe-
male) rat pups were treated with ketamine hydrochloride 
(Ketaset, Fort Dodge Animal Health, Fort Dodge, IA). Pups 
were randomly assigned to treated and control groups for 
histochemical and gene array studies (n = 5/group). All ani-
mal procedures were approved by the Institutional Animal 
Care and Use Committee of the National Center for Toxico-
logical Research and performed in accordance with the Pub-
lic Health Service Policy on Humane Care and Use of Labo-
ratory Animals. Ketamine was diluted in saline and adminis-
tered subcutaneously at doses of 5, 10, or 20 mg/kg, in one, 
three or six injections at 2-h intervals. Control animals re-
ceived saline at the same time points. Between each injection 
animals were returned to their dam to help maintain body 
temperature and reduce stress. All animals were sacrificed 6-
h after the last injection by either decapitation for RNA iso-
lation and in situ hybridization or via transaortic perfusion 
with 0.9% saline and 4% paraformaldehyde in 0.1 M phos-
phate
 buffer (pH 7.2) for morphological studies.  
Measurement of Ketamine in Rat Brain and Plasma 
  Rats treated with six injections of 20 mg/kg ketamine or 
saline were sacrificed at 5 min, 1, 2, 4, 6, and 18 h following 
the last injection. Blood and brain tissues from frontal cortex 
were collected for analyses of ketamine levels. 
Electron Microscopy (EM) 
  The nature of the ketamine-induced neurodegeneration 
was examined using EM. The frontal cortex was fixed in 4% 
paraformaldehyde and 0.1% glutaraldehyde in 0.1M phos-
phate buffer (pH 7.4) and postfixed with 1% osmium tetrox-
ide in 0.1M cacodylate buffer, subsequently washed with 
25% and 50% ethanol plus 5% uranyl acetate, followed by 
dehydration in an ascending ethanol series and embedded in 
Epon. The frontal cortex thin sections were stained with 
uranyl acetate and lead citrate and examined at 60 kV using a 
Philips CM100 electron microscope (FEI Corporation, Eind-
hoven, Netherlands). 
In Situ Hybridization 
  An oligonucleotide probe complementary to the mRNA 
encoding the NMDA receptor NR1 subunit was selected 
based on cloned cDNA sequences. The sequence of the 
probe used for in situ hybridization was as follows: 5’-
TTCCTCCTCCTCCTC-ACTGTTCACCTT-GAATCGGCC- 
AAAGGGACT (this corresponds to a region that is constant 
across all NR1 splice variants). [
35S] deoxy-ATP (New Eng-
land Nuclear, Boston, MA) and terminal deoxy-nucleotidyl 
transferase (Boehringer Mannheim Corp., Indianapolis, IN) 
were used to label the 3’ end and attain specific activities of 
approximately 5–8 x10 cpm/g. The specificity of the probes 
has been described by Monyer et al., [9] and Moriyoshi   
et al., [10]. Coronal sections (10 m) through the frontal 
cortex were cut with a cryostat, rinsed in PBS and processed 
for in situ hybridization as described previously [11]. After 
an overnight hybridization at 41
oC, slides were washed in 
4, 1, and 0.1 sodium chloride-sodium citrate solution, 
dehydrated in 70% ethanol and air-dried. Autoradiography 
was performed using Kodak (Rochester, NY) NTB3 emul-
sion; slides were exposed for 3 weeks at 4
oC. Hematoxylin-
eosin counterstaining was performed to aid in the analysis of 
the in situ hybridization autoradiographs. 
RNA Isolation 
  Brain tissue from frontal cortex was collected for RNA 
isolation.  Total RNA was extracted using RNeasy
® Lipid 
Tissue Mini Kits (Qiagen Inc., Valencia, CA). The RNA 
yield was examined spectrophotometrically by measuring   
the optical density at 260 nm. The purity and quality of   
the extracted total RNA were evaluated using the RNA   
6000 LabChip kit and Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). High quality RNA [with RNA 
integrity numbers (RINs) greater than 8.5] was used for the 
microarray experiments and TaqMan gene expression assays. 
Microarray Analysis 
  To identify signatures in gene expression profiles associ-
ated with ketamine treatment, a microarray technique was 
used to examine the gene expression patterns in PND 7 rat 
brains. Gene expression profiling was performed with the 
Illumina Rat Ref-12 Expression BeadChip platform that con-
tains 22,226 probes (Illumina Inc., San Diego, CA). Data 
from the Illumina were further input into ArrayTrack, a 
software system developed by NCTR/FDA for the manage-
ment, analysis, visualization and interpretation of microarray 
data.  Clustering analyses were conducted using Array-
Track™. Gene function analysis of Gene Ontology was con-
ducted using FatiGO+ (a web-based bioinformatics tool for 
the functional
 profiling of genome-scale experiments specifi-
cally oriented for the interpretation of microarray experi-
ments) [12] and GOFFA [13]. 
RESULTS 
Ketamine Levels in Plasma and Brain 
  5 min after ketamine injection, ketamine levels in plasma 
were highest (5.80 ± 3.10 g/ml) and decreased to 0.01 ± 
0.01 g/ml (mean ± SEM) at 18 h. Ketamine levels in brain 
tissue were lower than in plasma, but similar to plasma in 
terms of time course: ketamine levels in brain were highest 
at 5 min (2.65 ± 1.60 g/g) after ketamine administration and 
decreased to 0.03 ± 0.02 g/g at 18 h. Ketamine concentra-
tions in plasma and brain decreased in a manner consistent 
with a single elimination process with a half-lives of 0.68 
and 0.90 h, respectively [14]. 
Ketamine-Induced Neurotoxicity 
  At the EM level, DNA degradation and chromosome 
condensation were observed in layers II and III of the frontal 
cortex of PND-7 rats after 6 ketamine (20 mg/kg) injections, 
providing direct evidence of neuronal cell death (Fig. 1B). 
DNA degradation and chromosome condensation indicate 
advanced states of apoptosis. The control animals showed 
normal cortical neurons with an intact cytoplasm and nuclear 
membrane (Fig. 1A).  
  No obvious detrimental effects were observed in animals 
injected with 20 mg/kg ketamine either one or three times, 
indicating that shorter exposure durations and lower doses 
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no significant increase in cell death was detected in rat brains 
exposed to 5 or 10 mg/kg of ketamine in single or multiple 
injections (three or six times) compared to controls [14]. In 
the present study, quantitative examinations were carried out 
on several major brain regions including striatum, hippo-
campus, thalamus and amygdala. Repeated ketamine injec-
tions (20 mg/kg  6) caused a more than 10-fold increase in 
neuronal damage in the frontal cortex and around a 3-fold 
increase in the striatum, hippocampus, thalamus, and 
amygdala as revealed using immunohistochemical and   
morphological methods. These data suggest that the frontal 
cortex is the region most vulnerable to ketamine-induced 
neurotoxicity during the development [14]. 
 
 
 
 
 
 
 
 
Fig. (1). Electron Micrographs (EM) showing a normal neuron in 
frontal cortex with intact cytoplasm and nuclear membrane from a 
control rat (PND 7) brain (A). The EM in (B) shows the typical 
nuclear fragmentation representing apoptosis in layers II and III of 
the frontal cortex from a ketamine- (20 mg/kg x 6 injections) 
treated rat brain. 
Ketamine-Induced Alterations in NMDA Receptor   
Expression (In Situ Hybridization Studies) 
  NMDA receptor NR1 subunit mRNA was abundant in 
both control and ketamine-treated (20 mg/kg x 6 injections) 
rats.  The autoradiograph grain density of NR1 mRNA in 
layers II and III of the frontal cortex was increased in treated 
rats (Fig. 2) and the locations of these increases corre-
sponded to the areas where the most damaged neurons were 
detected. Quantitative analysis of the NR1 in situ hybridiza-
tion signal demonstrated a significant difference between 
control and ketamine-treated rats (data not shown) and   
suggests that the neurodegeneration in the frontal cortex of 
ketamine treated animals is associated with an up-regulation 
of the NMDA NR1 subunit. 
DNA Microarray Analysis 
  Microarray data analysis was performed using Array-
Track™. The criteria for identifying differentially expressed 
genes (DEGs) were fold-changes greater than 1.4 (up or 
down) and P-values less than 0.05 (in comparison to the   
control group). There were 819 genes that satisfied these 
requirements. We performed the functional enrichment of 
Gene Ontology terms and found that these 819 DEGs were 
associated with 31 significant terms or pathways including: 
developmental processes; growth; biological processes;   
differentiation; behavioral patterns; and receptor activity. In 
addition, 15 genes relevant to or associated with apoptosis 
were up-regulated and 17 were down-regulated (Table 1) [15] 
and four receptor signaling pathways (glutamate, GABA, 
dopamine and aryl hydrocarbon) were identified [15]. 
 
 
 
 
 
 
 
 
 
Fig. (2). NMDA receptor NR1 subunit mRNA levels assessed by in 
situ hybridization in PND 7 rat brains using a 
35S-labeled oligonu-
cleotide probe specific for the NMDA receptor NR1 subunit. 
TaqMan Gene Expression Assays 
  The expression levels of genes associated with NMDA 
receptor subunits were measured with quantitative PCR (Q-
PCR) using TaqMan assays (Applied Biosystems). Consis-
tent with the microarray results, the expression of genes as-
sociated with NMDA receptor NR1, NR2A and NR2C 
subunits was significantly higher in ketamine treated ani-
mals: no significant effects were observed for genes encog-
ing NR2B or NR2D subunits (Table 2) [15].  
DISCUSSION 
  To date, data from both rodents and nonhuman primates 
have demonstrated the neurotoxic effects of ketamine on the 
developing brain [2, 4, 6, 7]. These findings have raised con-
cerns regarding the safe administration of ketamine in the 
obstetric and pediatric setting. Further experiments are 
needed to determine the clinical significance of the animal 
observations, particularly in light of the fact that the animal 
studies showing ketamine-induced toxicity have been carried 
out in intact animals, not in animals undergoing surgical or 
other traumatic procedures.  
  Consistent with the previous data of Ikonomidou et al. 
[2], the present study demonstrated that lower doses and 
shorter exposure durations of ketamine treatment did not 
result in neurotoxicity in the developing rat brain. The cell 
death induced by ketamine was dose and exposure duration 
dependent. Ketamine levels in plasma and brain were highest 
soon after the last exposure, decreased rapidly thereafter, and 
were undetectable within 6 h [14]. An interesting observation 
is that the time course of plasma and brain ketamine levels 
do not parallel that for neuronal cell death: when plasma and 
brain ketamine had decreased to near zero, neuronal cell 
death was increasing significantly [14]. Meanwhile, in-
creases in NMDA receptor NR1 subunit mRNA levels, as 
demonstrated using in situ hybridization techniques, ap-
peared to be highest in the frontal cortical areas where the 
most severe neurodegeneration was observed. One explana-
tion for these observations is that the enhanced cell death 
caused by ketamine is closely associated in time with altered 
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NMDA receptor expression and not in situ plasma or brain 
tissue ketamine levels. 
  Several lines of evidence indicate that activation of 
NMDA receptors causes apoptosis and necrosis [4, 5, 16-20]. 
In nonhuman primates, ketamine-induced neuronal death is 
characterized by both apoptosis and necrosis [4, 5]. In ro-
dents, however, most evidence indicates that apoptosis is the 
major cell death pathway caused by NMDA receptor antago-
nists [17-20]. Several factors may contribute to these differ-
ences in ketamine-induced neurodegeneration, such as spe-
cies, developmental stage at the time of drug exposure, doses 
and duration of exposure, etc. In the studies described herein, 
Table 1.  Apoptosis Related Genes Identified by GOFFA (Ref. [15]) 
   Gene Symbols  Gene Names 
1  Acvr1c  activin A receptor, type IC 
2  Ahr  aryl hydrocarbon receptor 
3  Alms1  Alstrom syndrome 1 
4  Amigo2  adhesion molecule with Ig like domain 2 
5  Atp7a  ATPase, Cu++ transporting, alpha polypeptide 
6  Bnip3  BCL2/adenovirus E1B 19 kDa-interacting protein 3 
7  Bub1b  budding uninhibited by benzimidazoles 1 homolog, beta  
8  Cd24  CD24 antigen 
9  Cdc2a  cell division cycle 2 homolog A (S. pombe) 
10  Inhba  inhibin beta-A 
11  Myc  myelocytomatosis oncogene 
12  Ntf3  neurotrophin 3 
13  Pak7_predicted  p21 (CDKN1A)-activated kinase 7 (predicted) 
14  Pdia2_predicted  protein disulfide isomerase associated 2 (predicted) 
15  Rasa1  RAS p21 protein activator 1 
16  Tnfrsf11b  tumor necrosis factor receptor superfamily, member 11b  
17  Unc5c  unc-5 homolog C (C. elegans) 
18  Agt  angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
19  Alb  Albumin 
20  Apoe  apolipoprotein E 
21  Bag3  Bcl2-associated athanogene 3 
22  Cebpb  CCAAT/enhancer binding protein (C/EBP), beta 
23  Clu  Clusterin 
24  Cryab  crystallin, alpha B 
25  Gjb6  gap junction membrane channel protein beta 6 
26  Hrk  harakiri, BCL2 interacting protein (contains only BH3 domain) 
27  Igfbp3  insulin-like growth factor binding protein 3 
28  Inpp5d  inositol polyphosphate-5-phosphatase D 
29  Jun  Jun oncogene 
30  Mal  myelin and lymphocyte protein, T-cell differentiation protein 
31  Rassf5  Ras association (RalGDS/AF-6) domain family 5 
32  Txnip  thioredoxin interacting protein 
Genes 1-17 were down-regulated and genes 18-32 were up-regulated. 260    Current Neuropharmacology, 2011, Vol. 9, No. 1  Liu et al. 
morphological data from electron microscopic (EM) obser-
vations showed that neuronal cell death in rats was primarily 
apoptotic in nature [14]. In addition to the EM data, caspase-
3 and Fluoro-Jade C staining support the hypothesis that 
ketamine-induced neuronal cell death in rats is apoptotics in 
nature [14, 21]. 
  Based on our morphological observations that the most 
severe neuronal damage seen after ketamine exposure oc-
curred in the frontal cortex, tissue from that area was se-
lected for RNA isolation and microarray analysis. The mi-
croarray data revealed that the expression of 32 apoptosis-
relevant genes were altered in ketamine treated rat brains. 
Apoptosis-related genes have two distinct roles, to either 
augment or diminish apoptosis and the final fate of a cell is 
determined by the balance between these two actions. 
Among the 32 apoptosis-relevant genes, 10 (out of 15) up-
regulated genes were pro-apoptotic and almost half of the 
down-regulated genes were anti-apoptotic [15]. Although 
microarray data analysis did not detect changes in the ex-
pression of some pro-apoptotic genes such as caspase-3, it is 
likely that changes in gene expression will vary at different 
time points. Moreover, cleaved caspase-3, which is formed 
by a post-translational modification of caspase-3, is the ac-
tive form of casapse-3. Therefore, it is possible that at the 
transcriptional level, caspase-3 gene expression in ketamine 
treated rats will be similar to that of control rats. 
  Some critical changes in gene expression--as determined 
from the microarray analysis--were confirmed using QPCR. 
We hypothesized that the cell death caused by ketamine oc-
curred through a compensatory up-regulation of specific 
NMDA receptor subunits, such as NR1. This up-regulation 
then makes neurons which possess these receptors more vul-
nerable to the excitotoxic effects of endogenous glutamate 
after ketamine has left the system (near zero plasma and 
brain levels) and, thus, left these receptors uninhibited. The 
resulting over-excitation of cells harboring upregulated 
NMDA receptors results in a dysregulation of calcium sig-
naling, increased oxidative stress [19], and activation of the 
NF-kB signaling pathway [7]. Indeed, in situ hybridization, 
microarray analysis and Q-PCR consistently demonstrated 
higher NR1 expression in ketamine treated rat brains [15]. In 
addition to NR1, gene expression for the NMDA receptor 
subunits NR2A and NR2C was also found to be higher in 
ketamine treated rats [15]. Moreover, we showed in our pre-
vious studies that ketamine-induced neurodegeneration was 
blocked by NR1 antisense oligonucleotides in cultured rat 
and monkey neurons [6, 7] providing additional evidence 
supporting this hypothesis.  
  Taken together, the present data suggest that ketamine 
causes increased apoptosis in developing rat brains in a dose 
and exposure duration dependent manner. Plasma and brain 
tissue ketamine levels do not correlate in time with the oc-
currence of cell death, which occurs after when ketamine 
levels are quite low. Ketamine administration stimulates the 
up-regulation of NMDA receptor subunits which may further 
activate pro-apoptotic genes through various pathways and 
trigger apoptosis.  
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